Actively Recruiting

Phase 4
Age: 18Years - 100Years
All Genders
NCT03340506

Dabrafenib and/or Trametinib Rollover Study

Led by Novartis Pharmaceuticals · Updated on 2026-04-20

100

Participants Needed

28

Research Sites

782 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

CONDITIONS

Official Title

Dabrafenib and/or Trametinib Rollover Study

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
  • In the opinion of the Investigator would benefit from continued treatment.
Not Eligible

You will not qualify if you...

  • Patient has been previously permanently discontinued from study treatment in the parent protocol.
  • Patient's indication is commercially available and reimbursed in the local country.
  • Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 28 locations

1

Honor Health Research Institute

Scottsdale, Arizona, United States, 85258

Active, Not Recruiting

2

Honor Health Research Institute

Scottsdale, Arizona, United States, 85258

Actively Recruiting

3

National Institute Of Health

Bethesda, Maryland, United States, 20892

Active, Not Recruiting

4

James Cancer Hospital and Solove Research Institute Ohio State

Columbus, Ohio, United States, 43210

Completed

5

Mary Crowley Cancer Research

Dallas, Texas, United States, 75251

Completed

6

Novartis Investigative Site

Caba, Buenos Aires, Argentina, C1121ABE

Completed

7

Novartis Investigative Site

Innsbruck, Tyrol, Austria, 6020

Active, Not Recruiting

8

Novartis Investigative Site

Beijing, China, 100036

Completed

9

Novartis Investigative Site

Copenhagen, Denmark, DK-2100

Active, Not Recruiting

10

Novartis Investigative Site

Lyon, France, 69373

Active, Not Recruiting

11

Novartis Investigative Site

Nantes, France, 44093

Active, Not Recruiting

12

Novartis Investigative Site

Paris, France, 75970

Completed

13

Novartis Investigative Site

Villejuif, France, 94800

Completed

14

Novartis Investigative Site

Mannheim, Baden-Wurttemberg, Germany, 68305

Completed

15

Novartis Investigative Site

Berlin, Germany, 13353

Completed

16

Novartis Investigative Site

Hamburg, Germany, 20246

Completed

17

Novartis Investigative Site

Heidelberg, Germany, 69120

Active, Not Recruiting

18

Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, Hungary, 4032

Completed

19

Novartis Investigative Site

Budapest, Hungary, H 1122

Completed

20

Novartis Investigative Site

Kashiwa, Chiba, Japan, 277-8577

Completed

21

Novartis Investigative Site

Chuo Ku, Tokyo, Japan, 1040045

Completed

22

Novartis Investigative Site

Rotterdam, South Holland, Netherlands, 3015 GD

Completed

23

Novartis Investigative Site

Utrecht, Netherlands, 3584 CX

Active, Not Recruiting

24

Novartis Investigative Site

Barcelona, Spain, 08035

Actively Recruiting

25

Novartis Investigative Site

Madrid, Spain, 28040

Actively Recruiting

26

Novartis Investigative Site

Madrid, Spain, 28041

Completed

27

Novartis Investigative Site

Madrid, Spain, 28050

Actively Recruiting

28

Novartis Investigative Site

Songkhla, Hat Yai, Thailand, 90110

Active, Not Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here